<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281294</url>
  </required_header>
  <id_info>
    <org_study_id>ZAF-711</org_study_id>
    <nct_id>NCT00281294</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PDL BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Facet Biotech</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as
      determined by a 50% improvement of an American College of Rheumatology criteria (ACR50)
      response at Week 14 (Stage A of study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as
      determined by a 50% improvement of an American College of Rheumatology criteria (ACR50)
      response at Week 14 (Stage A of study).

      Stage B of this trial is Double blind.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early because the first phase didn't meet the endpoint.
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-Proportion of subjects achieving an American College of Rheumatology response (ACR50) at Week 14 (Stage A).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving ACR20, ACR50, and ACR70 (Stages A and B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum CRP values (Stages A and B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent improvement in individual ACR core outcome measures (Stages A and B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28-CRP and ACR-N (Stages A and B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR-N at each dosing day and at 1 and 3 months after the last dose of study drug (Stages A and B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of subjects experiencing a disease flare-up since Week 14 (Stage B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease flare since Week 14 (Stage B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of fontolizumab throughout the study by collection of the following:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and SAEs up to 84 days after last dose of study drug; and, opportunistic or medically significant infections, malignancies, and onset of autoimmune diseases up to 6 months after last dose of study drug</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory measurements (hematology, serum chemistry) up to 84 days after last dose of study drug</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics (PK) up to 6 months after last dose of study drug (Stages A and B)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity up to 6 months after last dose of study drug (Stages A and B)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fontolizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, at least 18 years of age

          -  A diagnosis of RA according to ACR criteria (Appendix D, American College of
             Rheumatology Clinical Classification Criteria for Rheumatoid Arthritis)

          -  RA functional class I, II, or III (Appendix E, ACR Revised Criteria for Classification
             of Functional Status in Rheumatoid Arthritis ) for at least 6 months

          -  Active RA with ≥ 6 tender joints and ≥ 6 swollen joints within one week of dosing or
             on Day 0, before dosing

          -  Serum CRP ≥ 1.0 mg/dL (10 mg/L) or ≥ 45 minutes of morning stiffness

          -  On stable doses for at least 30 days before receiving study drug of at least one, but
             not more than two, of the following disease-modifying antirheumatic drugs (DMARDs):
             hydroxychloroquine, leflunomide, methotrexate (leflunomide-methotrexate combination is
             unacceptable), or sulfasalazine. If being treated with nonsteroidal anti-inflammatory
             drugs (NSAIDs) or low-dose prednisone (≤ 10 mg/day), must be on stable regimen for at
             least 14 days before receiving study drug

          -  Women of childbearing potential with a negative serum pregnancy test at screening

          -  Subjects with reproductive potential agree to use a double-barrier method of
             contraception during the study and for 3 months after receiving last dose of study
             drug

          -  Must provide a signed and dated informed consent and an authorization to use protected
             health information, have the ability to understand the study requirements, and comply
             with study procedures, including required study visits

        Exclusion Criteria:

          -  Significant involvement of secondary RA (eg, Felty's syndrome, pulmonary fibrosis,
             Sjogren's syndrome, vasculitis (keratoconjunctivitis sicca is not exclusionary)

          -  Received a live vaccine within 30 days of receiving fontolizumab

          -  Received an investigational agent within 30 days or five half-lives of the agent,
             whichever is longer, of receiving fontolizumab

          -  Received a corticosteroid injection into any joint, or has been treated with &gt; 10
             mg/day of a corticosteroid within 30 days of receiving fontolizumab

          -  Received etanercept or anakinra within 30 days of receiving fontolizumab

          -  Received gold salts, infliximab, or adalimumab within 60 days of receiving
             fontolizumab

          -  Received IV gamma-globulin or Prosorba column therapy within 90 days of receiving
             fontolizumab

          -  Received rituximab or cyclophosphamide within 6 months of receiving fontolizumab

          -  Failed B cell recovery after exposure to rituximab

          -  History of hypersensitivity to glycine, histidine, or Polysorbate 80

          -  Pregnant women or nursing mothers

          -  Malignancy within 5 years (excluding basal or squamous cell carcinoma of the skin or
             adequately treated cervical carcinoma in situ)

          -  Known chronic viral infections with HIV, hepatitis B, or hepatitis C

          -  Clinical, PPD, or clear radiographic evidence of prior TB

          -  Infection requiring hospitalization or parenteral medication, such as an antibiotic,
             antiviral, antifungal, or antiparasitic agent, within 90 days of receiving
             fontolizumab

          -  History of inflammatory joint disease (eg, gout, Lyme disease, psoriatic arthritis,
             reactive arthritis, seronegative spondyloarthropathy) or chronic inflammatory diseases
             (eg, inflammatory bowel disease, inflammatory myopathy, multiple sclerosis, overlap
             syndrome, scleroderma, systemic lupus erythematosus) other than RA

          -  Clinically significant unstable or poorly controlled acute or chronic diseases, such
             as myocardial infarction within 6 months, unstable angina, poorly controlled diabetes
             or hypertension

          -  ALT &gt; 1.5 × the upper limit of normal; AST &gt; 1.5 × the upper limit of normal;
             creatinine 1.5 × the upper limit of normal; absolute neutrophil count (ANC) &lt;
             1000/mm3; platelet count &lt; 50,000/mm3

          -  History of any other medical disease, laboratory abnormalities, or psychological
             conditions that would make the subject (based upon the principal investigator's
             judgment) unsuitable for study enrollment

          -  Current abuse of alcohol or drugs (based upon investigator's assessment)

          -  Major surgery within 3 months prior to or planned elective surgery during or within 3
             months after last dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark C. Genovese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Medical Center-Div. of Rheumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Molitor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benaroya Research Institute at Virginia Mason</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael H. Schiff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Arthritis Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Kivitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altoona Center for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Wiesenhutter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coeur d Alene Arthritis Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Justus J. Fiechtner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Justus Fiechtner MD PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Wallace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wallace Rheumatic Study Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Kremer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Rheumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert S. Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Associates Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wallace Rheumatic Study Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center-Div. of Rheumatology</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coeur d Alene Arthritis Clinic</name>
      <address>
        <city>Coeur d Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus J. Fiechtner MD PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910-8595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pdl.com</url>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <last_update_submitted>August 2, 2008</last_update_submitted>
  <last_update_submitted_qc>August 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2008</last_update_posted>
  <keyword>Arthritis, Rheumatoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

